Steven Cohen Immatics N.V. Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$7.36 - $10.89 $2.09 Million - $3.1 Million	-284,315 Reduced 80.93%	67,015 $705,000
Q3 2023 Nov 14, 2023	BUY	$11.01 - $12.62 $160,922 - $184,453	14,616 Added 4.34%	351,330 $4.07 Million
Q2 2023 Aug 14, 2023	SELL	$5.92 - $12.72 $2.43 Million - $5.23 Million	-410,786 Reduced 54.95%	336,714 $3.89 Million
Q1 2023 May 15, 2023	BUY	$6.74 - $9.44 $2.85 Million - $3.99 Million	422,500 Added 130.0%	747,500 $5.16 Million
Q4 2022 Feb 14, 2023	BUY	$8.05 - $11.58 $759,920 - $1.09 Million	94,400 Added 40.94%	325,000 $2.83 Million
Q3 2022 Nov 14, 2022	BUY	$3.31 - $13.06 $763,286 - $3.01 Million	230,600 New	230,600 $2.31 Million

76.6M

571K

210K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $894M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.